Company / Total Assets
Myriad Genetics, Inc. Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$706.6M
FY2025
5-year range
$706.6M / $1.3B
FY2021-FY2025
Trend
-31.2%
vs FY2024
Sector context
#108 of 214
Health Care
What the data says
At $707M, Myriad Genetics, Inc.'s total assets ranks #108 of 214 in the Health Care sector. Total Assets has declined for 6 consecutive years, from $1.6B in FY2019 to $707M in FY2025.
Based on SEC 10-K filings.
$707M in FY2025 with a 5-year CAGR of -13.0%.
Declined from $1.1B to $707M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- -16.2%
- 5-Year CAGR
- -13.0%
- 10-Year CAGR
- -
Sector benchmark
#108 of 214 in Health CareTop 50% of 214This company $706.6M Sector average $7.5B
▼
-90.5% below sector average
Key checks
Key Insights
- Myriad Genetics, Inc.'s total assets has declined for 6 consecutive years.
- 5-year CAGR of -13.0%, indicating a declining trend.
- In FY2025, total assets decreased 31.2% year-over-year.
- Ranks #108 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $706.6M | -31.2% |
| FY2024 | $1.0B | -10.4% |
| FY2023 | $1.1B | -4.4% |
| FY2022 | $1.2B | -9.2% |
| FY2021 | $1.3B | -6.9% |
| FY2020 | $1.4B | -9.2% |
| FY2019 | $1.6B | +33.0% |
| FY2018 | $1.2B | -2.8% |
| FY2017 | $1.2B | +37.3% |
| FY2016 | $880.5M | +14.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026